We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
-13.52%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$641M
AUM Growth
-$134M
(-17%)
Cap. Flow
-$30.9M
Cap. Flow
% of AUM
-4.83%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
88
New
23
Increased
22
Reduced
22
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SkinHealth Systems
SKIN
|
+$40.8M |
| 2 |
Organogenesis Holdings
ORGO
|
+$16.9M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$15.1M |
| 4 |
AnaptysBio
ANAB
|
+$14.3M |
| 5 |
CUTR
Cutera, Inc.
CUTR
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$21.8M |
| 2 |
OraSure Technologies
OSUR
|
+$20.7M |
| 3 |
HOLX
Hologic
HOLX
|
+$17.3M |
| 4 |
Smith & Nephew
SNN
|
+$12.3M |
| 5 |
10x Genomics
TXG
|
+$8.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.21% |
| 2 | Consumer Staples | 6.57% |
| 3 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Lantheus
LNTH
$6.58B
| $3.65M | 0.57% |
55,222
-123,205
| -69% | -$7.77M |
|
52
DexCom
DXCM
$32.9B
| $3.52M | 0.55% |
47,236
+800
| +2% | +$73K |
|
|
LYRA
53
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $3.35M | 0.52% |
+11,848
| New | +$3.23M |
|
|
KYNB
54
Kyntra Bio
KYNB
$28.1M
| $3.19M | 0.5% |
12,089
-30,485
| -72% | -$7.79M |
|
|
IOBT
55
DELISTED
IO Biotech
IOBT
| $3.06M | 0.48% |
655,404
-17,330
| -3% | -$106K |
|
56
Alnylam Pharmaceuticals
ALNY
$29B
| $2.93M | 0.46% |
+20,100
| New | +$2.85M |
|
57
Xenon Pharmaceuticals
XENE
$6.13B
| $2.28M | 0.36% |
75,000
-114,797
| -60% | -$3.47M |
|
58
C4 Therapeutics
CCCC
$396M
| $2.13M | 0.33% |
282,640
+115,904
| +70% | +$1.02M |
|
|
KZR
59
DELISTED
Kezar Life Sciences
KZR
| $2.08M | 0.33% |
+25,200
| New | +$2.22M |
|
|
YMAB
60
DELISTED
Y-mAbs Therapeutics
YMAB
| $2.06M | 0.32% |
136,182
-102,800
| -43% | -$1.2M |
|
61
Verastem
VSTM
$503M
| $1.91M | 0.3% |
137,042
| – | – |
|
62
PepGen
PEPG
$129M
| $1.74M | 0.27% |
+175,000
| New | +$1.95M |
|
|
KDNY
63
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.54M | 0.24% |
+88,000
| New | +$1.38M |
|
64
CRISPR Therapeutics
CRSP
$5.17B
| $1.34M | 0.21% |
22,000
| – | – |
|
65
Xilio Therapeutics
XLO
$60.7M
| $1.32M | 0.21% |
32,404
-1,703
| -5% | -$90.1K |
|
66
Cullinan Oncology
CGEM
$1.06B
| $1.22M | 0.19% |
+95,485
| New | +$1.08M |
|
67
Outset Medical
OM
$97.1M
| $1.03M | 0.16% |
+4,613
| New | +$1.98M |
|
68
NovoCure
NVCR
$1.88B
| $923K | 0.14% |
13,275
-4,000
| -23% | -$301K |
|
69
Immunic
IMUX
$193M
| $833K | 0.13% |
24,000
| – | – |
|
70
VistaGen Therapeutics
VTGN
$11.6M
| $726K | 0.11% |
+27,500
| New | +$971K |
|
|
DALS
71
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $485K | 0.08% |
50,000
-50,000
| -50% | -$486K |
|
72
Celldex Therapeutics
CLDX
$3.04B
| – | – |
-69,000
| Closed | -$2.35M |
|
73
Cytek Biosciences
CTKB
$554M
| – | – |
-180,000
| Closed | -$1.94M |
|
|
HOLX
74
DELISTED
Hologic
HOLX
| – | – |
-225,600
| Closed | -$17.3M |
|
|
75
Illumina
ILMN
$29.9B
| – | – |
-64,044
| Closed | -$21.8M |
|
Similar funds
TW
M
SG
BL
FFA
GWM
Q
SIM
Soleus Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Soleus Capital Management held 88 positions worth $641M, down 17% from $775M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Soleus Capital Management withdrew a net $30.9M in Q2 2022, closing 16 positions and reducing 22 holdings. Its most notable exit was Illumina, an estimated $21.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 80% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Soleus Capital Management opened a new position in Tandem Diabetes Care worth $10.9M.
- Soleus Capital Management's largest Q2 2022 buy was Tandem Diabetes Care: 183,800 shares worth $10.9M.
- Soleus Capital Management added most to SkinHealth Systems in Q2 2022, an estimated $40.8M increase.
- Soleus Capital Management's biggest Q2 2022 reduction was Kyntra Bio, cutting an estimated $7.79M.
- Soleus Capital Management fully exited Illumina in Q2 2022, selling an estimated $21.8M.
- Soleus Capital Management's ten largest holdings make up 43% of its $641M portfolio in Q2 2022.
- Soleus Capital Management opened 23 new positions and closed 16 in Q2 2022.
- Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $641M.
Based on Soleus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.